

**Waldenstrom's Macroglobulinemia Foundation of Canada**

**2018 Financial Statements**

**Balance Sheet as at December 31, 2018**

<b>Assets</b>	<b>2017</b>	<b>2018</b>
Cash in Bank Accounts	\$107,483	\$173,914
Short Term Investments	200,000	69,485
Sales Tax Receivable	412	909
Prepaid Expense	0	496
Total Assets	307,895	244,804
<b>Liabilities</b>		
Research Grants (Note 4)	0	104,717
Accounts payable	509	669
Total Liabilities	509	105,386
<b>Equity</b>		
Retained Earnings	307,386	139,418
Total Liability and Retained Earnings	307,895	244,804

Approved on behalf of the Board

Signed

A. Hinchcliffe, Director and President

D. R. Johnston, Director and Treasurer

## Statement of Revenue and Expense for the two years ended December 31, 2018

	2017	2018
Revenue		
Membership Contributions	\$19,585	\$24,022
Research Contributions	41,700	26,888
Fundraising Activities	29,991	0
Educational Forums (Note 5)	0	1,675
Interest Income	0	1,660
Total Revenue	91,276	54,245
Expense		
Research Grants (Note 4)	(21,404)	202,974
Educational Forums (Note 5)	0	5,882
Professional and Accounting Fees	4,849	5,785
Bank and Credit Card Fees	844	918
Website and Computer Services	228	446
Office Supplies and Postage	2,330	2,174
Support Groups Services	2,308	2,436
Insurance	0	540
Miscellaneous	65	1,058
Total Expense	(10,779)	222,213
Excess of Revenue over Expense	\$102,056	\$(167,968)

## Statement of Retained Earnings for the two years ended December 31, 2018

Balance, beginning of year	\$205,330	\$307,386
Excess of Revenue over Expense	102,056	(167,968)
Balance, end of year	\$307,386	\$139,418

### Notes to the Financial Statements

#### 1. Accounting Policies

Contributions are recorded as revenue when made. Expenses are recorded on an accrual basis as incurred. Amounts in US\$ are converted to Canadian\$ based on actual cost.

#### 2. Incorporation and Status

The Foundation was incorporated as a corporation without share capital under the Laws of Ontario on October 5, 2001. It received notification of registration as a charity under the provisions of the Income Tax Act effective December 27, 2002. It commenced

operations in 2003. The foundation has been designated as a charitable organization for the purposes of the Income Tax Act (148(I)(f)).

### 3. Objects

The objects of the Foundation are: To receive and maintain a fund or funds and to apply all or part of the principal and income therefrom, from time to time, for charitable purposes, and in particular for the following purposes: (a) to undertake public education, family support services, dissemination and publication of information about Waldenstrom's Macroglobulinemia, and (b) to promote and provide funds for research in the cause, control and cure of Waldenstrom's Macroglobulinemia.

### 4. Research Grants

The negative expense shown for 2017 is the amount refunded to the foundation in 2017 from Grants in prior years for a research project that could not be completed. In 2018, the Foundation agreed to fund a research project in the U. S. with a total expected cost of US\$155,000 (CAN\$202,974). An amount of US\$75,000 (CAN\$98,257) was paid in 2018 and a liability of CAN\$104,717 has been held for amounts that remained to be paid after 2018.

### 5. Educational Forums

The Foundation holds Educational Forums from time to time. In 2018, an Educational Forum was held in Halifax.

### 6. Board of Directors

Arlene Hinchcliffe, President  
Betty McPhee, Vice-President  
David Johnston, Treasurer  
Raffaella Mercurio  
J. A. Clancy  
Paul Kitchen